ND: |
ME09001835 |
PMID: |
9001835 |
LR: |
20061115 |
CED: |
19970408 |
DCO: |
19970408 |
Autoren: |
Talent JM; Gracy RW |
Titel: |
Pilot study of oral polymeric N-acetyl-D-glucosamine as a potential treatment for patients with osteoarthritis. |
Quelle: |
Clinical therapeutics; VOL: 18 (6); p. 1184-90 /1996 Nov-Dec/ |
PM: |
Print |
SU: |
IM |
Sprache: |
English |
CY: |
UNITED STATES |
JID: |
7706726 |
ISSN: |
0149-2918 |
CO: |
CLTHDG |
Institution: |
Department of Biochemistry and Molecular Biology, University of North Texas Health Science Center, Fort Worth, USA. |
DT: |
Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Schlagwörter |
CT: |
ABSORPTION; ACETYLGLUCOSAMINE/pharmacokinetics; ACETYLGLUCOSAMINE/*therapeutic use; ADMINISTRATION, ORAL; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; FEMALE; FOLLOW-UP STUDIES; GLUCOSAMINE/pharmacokinetics; GLUCOSAMINE/therapeutic use; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS/blood; OSTEOARTHRITIS/*drug therapy; PILOT PROJECTS; POLYMERS/pharmacokinetics; POLYMERS/therapeutic use; REFERENCE VALUES; TREATMENT OUTCOME |
CTG: |
ABSORPTION; ACETYLGLUCOSAMIN/Pharmakokinetik; ACETYLGLUCOSAMIN/*therapeutische Anwendung; APPLIKATION, ORALE; ERWACHSENER; CHROMATOGRAPHIE, HOCHDRUCK-FLÜSSIGKEITS-; CROSS-OVER-STUDIEN; WEIBLICH; VERLAUFSSTUDIEN; GLUCOSAMIN/Pharmakokinetik; GLUCOSAMIN/therapeutische Anwendung; HALBWERTZEIT; MENSCH; MÄNNLICH; MENSCHEN IM MITTLEREN LEBENSALTER; OSTEOARTHROSE/Blut; OSTEOARTHROSE/*Arzneimitteltherapie; PILOTPROJEKTE; POLYMERE/Pharmakokinetik; POLYMERE/therapeutische Anwendung; REFERENZWERTE; BEHANDLUNGSERGEBNIS |
TE: |
Polymers; Glucosamine/3416-24-8; Acetylglucosamine/7512-17-6 |
CR: |
3416-24-8; 7512-17-6 |
AB: |
Glucosamine and its derivatives, such as glucosamine sulfate and N-acetyl-D-glucosamine (NAG), have been shown to be effective in the treatment of patients with osteoarthritis. Unfortunately, the half-life of glucosamine in the blood is relatively short; therefore, a sustained-release form of the compound would be highly desirable. The purpose of this pilot study was to determine whether the polymeric form of NAG (POLY-Nag) could provide a longer-lasting oral source of NAG. Ten healthy subjects each ingested 1 g/d of either NAG or POLY-Nag for 3 days. After a 4-day washout period, each subject was crossed over to receive the other compound for 3 days. Serum samples were collected and analyzed using high-performance liquid chromatography. Results show that orally ingested NAG and POLY-Nag are absorbed, resulting in increased serum levels of NAG, and POLY-Nag appears to be at least as effective as NAG. Serum levels of NAG had decreased by 48 hours after cessation of ingestion of NAG or POLY-Nag but were still above baseline levels. Increases in serum glucosamine levels indicate that NAG and POLY-Nag are converted to glucosamine in vivo. In conclusion, POLY-Nag may provide a source of serum glucosamine for treatment of patients with osteoarthritis. Longer and more rigorous pharmaco-kinetic and clinical studies need to be done. |